Mike Boken, Shire
S
Mike Boken
Senior Director of Marketing, Vyvanse, Shire
BIG DEAL: Launching Prevnar, the first blockbuster vaccine
SUCCESS IS: 1 million Vyvanse scripts written 10 months after launch
You have to find a way to make your drug stand out from everybody else," says Mike Boken. He speaks from experience: Standing 7 feet tall, he never gets lost in the crowd.
Mike Boken
There's another truism that Boken lives by. As one of nine brothers and sisters, his mother expected chores to be done right—or else. "What I remember is that if you do it right the first time, you'll be in a better place."
Boken has applied that philosophy to promotion of Adderall XR and its ADHD follow up Vyvanse by developing smart adherence programs that keep patients on drug the first time around. It turns out that what's best for the patient is also best for the company: "We've seen the best ROIs coming from those retention programs."
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
March 25th 2025Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.
